Respiratory Complications of Rapidly Progressive Neuromuscular Syndromes: Guillain-Barré Syndrome and Myasthenia Gravis

ABSTRACT

Neuromuscular respiratory failure is a common complication of both the Guillain-Barré syndrome and myasthenia gravis. Several key pathophysiological mechanisms contribute to the spiral of respiratory insufficiency in these diseases, including inspiratory, expiratory, and bulbar muscle weakness. It is important to identify patients with impending respiratory failure early to avoid emergency intubations. Several clinical features and bedside pulmonary function tests (PFTs) are useful in guiding decisions about intubation. Weaning is initiated when respiratory muscles have recovered sufficiently, and again, PFT criteria are helpful. Intravenous immunoglobulin and plasmapheresis are the cornerstones of specific therapy for both illnesses when complicated by respiratory failure. Mortality and morbidity are dramatically increased by respiratory failure and are mainly due to associated medical complications. Optimal outcomes depend on avoidance of these and prompt implementation of immunomodulatory therapy.

KEYWORDS

Neuromuscular weakness - respiratory failure - plasmapheresis - IVIG - ICU

REFERENCES

• 1 Kurtzke J F. Epidemiology of MG.  Adv Neurol . 1978;  19 545
• 2 Osserman K E, Genkins G. Studies in myasthenia gravis: review of twenty year experience in over 1200 patients.  Mt Sinai J Med . 1971;  38 497
• 3 Thomas C E, Mayer S A, Gungor Y. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation.  Neurology . 1997;  48 1253-1260
• 4 Berrouschot J, Baumann I, Kalischewski P. Therapy of myasthenic crisis.  Crit Care Med . 1997;  25 1228-1235
• 5 Huges R A, Ress J H. Clinical and epidemiologic features of Guillain Barré syndrome.  J Infect Dis . 1997;  S92-S99
• 6 Ropper A H. Severe acute Guillain-Barré syndrome.  Neurology . 1986;  36 429-432
• 7 Ropper A H. The Guillain-Barré syndrome.  N Engl J Med . 1992;  326 1130-1135
• 8 Teitelbaum J S, Borel C O. Respiratory dysfunction in Guillian Barré syndrome.  Clin Chest Med . 1994;  15 705-714
• 9 Lawn N D, Flecther D D, Henderson R D, Wolter T D, Wijdicks E FM. Anticipating mechanical ventilation in Guillain-Barré syndrome.  Arch Neurol . 2001;  58 893-898
• 10 Fink M E. Treatment of critically ill patients with myasthenia gravis. In: Ropper AH, ed. Neurological and Neurosurgical Intensive care 3rd ed. New York: Raven Press 1993: 351-362
• 11 Heffner J E. Timing tracheostomy: calendar watching or individualization of care.  Chest . 1998;  114 361-363
• 12 Maziak D E, Meade M O, Todd T RJ. The timing of tracheostomy: a systematic review.  Chest . 1998;  114 605-609
• 13 Stock M C, Woodward C G, Shapiro B A. Perioperative complications of elective tracheostomy in critically ill patients.  Crit Care Med . 1986;  14 861-863
• 14 Lawn N D, Wijdicks E FM. Tracheostomy in Guillain-Barré syndrome.  Muscle Nerve . 1999;  22 1058-1062
• 15 The Plasma Exchange/Sandoglobin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997 349: 225-230
• 16 van der Meche G F, Schmitz P I, the Dutch Guillain Barré study group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome.  N Engl J Med . 1992;  326 1123-1129
• 17 French Cooperative Group on Plasma Exchange in Guillain Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987 22: 753-761
• 18 The Guillain-Barré Syndrome Study Group. Plasmapharesis and acute Guillian-Barré syndrome.  Neurology . 1985;  35 1096-1104
• 19 Couriel D, Weinstien R. Complications of therapeutic plasma exchange: a recent assessment.  J Clin Apheresis . 1994;  9 1-5
• 20 Wijdiks E FM. Guillain Barré syndrome. In: Wijdiks EFM, ed. The Clinical Practice of Critical Care Neurology New York: Lippincott-Raven Publishers 1997: 290-306
• 21 Kornfeld P, Ambinder E P, Mittag T. Plasmapheresis in refractory generalized myasthenia gravis.  Arch Neurol . 1981;  38 478-481
• 22 Antozzi C, Gemma M, Regi B. A short plasma exchange protocol is effective in severe myasthenia gravis.  J Neurol . 1991;  238 103-107
• 23 Thorlacius S, Aarli J A, Jacobson H. Plasma exchange in myasthenia gravis: clinical effect.  Acta Neurol Scand . 1985;  72 464-468
• 24 Stricker R B, Kwiatkowska B J, Habis J A. Myasthenic crises: response to plasmapheresis following failure of intravenous gammaglobulin.  Arch Neurol . 1993;  50 837-840
• 25 Arsura E L, Bick A, Brunner N G, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis.  Arch Intern Med . 1986;  146 1365-1368
• 26 Evoli A, Palmisani M T, Bartoccioni E, Padua L, Tonali P. High-dose intravenous immunoglobulin in myasthenia gravis.  Ital J Neurol Sci . 1993;  14 233-237
• 27 Jongen J L, van Doorn A P, van der Meche G F. High-dose intravenous immunoglobulin therapy for myasthenia gravis.  J Neurol . 1998;  245 26-31
• 28 Howard Jr F J. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis.  Neurology . 1998;  51(6 suppl 5) S30-S36
• 29 Mayer S A, Thomas C E. Therapy of myasthenic crisis.  Crit Care Med . 1998;  26 1136-1137
• 30 Winer J B, Hughes R AC. Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome.  Q J Med . 1988;  257 735-739
• 31 de Jager E A, Sluiter H J. Clinical signs in severe Guillain-Barré syndrome: analysis of 63 patients.  J Neurol Sci . 1991;  104 143-150
• 32 Roubenoff R A, Borel C O, Hanley D F. Hypermetabolism and hypercatbolism in Guillain-Barré syndrome.  J Parenter Enteral Nutr . 1992;  16 464-472
• 33 Moulin D E, Hagen N, Feasby T E, Amireh R, Hahn A. Pain in Guillain-Barré síndrome.  Neurology . 1997;  48 328-331
• 34 Tripathi M, Kaushik S. Carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit.  Crit Care Med . 2000;  28 655-658
• 35 Chaleha J A. Pearls and pitfalls in the intensive care management of Guillain Barré syndrome.  Seminars in Neurology . 2001;  21 399-405
• 36 Tether J E. Management of myasthenic and cholinergic crisis.  Am J Med . 1955;  19 740-742
• 37 Cohen M S, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death.  Ann NY Acad Sci . 1981;  377 670-677
• 38 Selecky P A, Ziment I. Prolonged respirator support for the treatment of intractable myasthenia gravis.  Chest . 1974;  65 207-209
• 39 Cornblath D R, Mellits E D, Griffin J W. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value.  Ann Neurol . 1988;  23 354-359
• 40 Winer J B, Hughes R AC, Greenwood R J, Perkin G D, Healy M JR. Prognosis in Guillain-Barré syndrome.  Lancet . 1985;  1 1202-1203
• 41 Winer J B, Hughes R AC, Osmond C. A prospective of acute idiopathic neuropathy: clinical features and their prognostic value.  J Neurol Neurosurg Psychiatry . 1988;  51 605-612
• 42 Fletcher D D, Lawn N D, Wolter T D, Wijdicks E FM. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation.  Neurology . 2000;  54 2311-2315
• 43 Mayer S A. Intensive care of myasthenic patient.  Neurology . 1997;  48 S70-S75